Ceftriaxone‐induced liver injury: Incidence, phenotypic characterization and predictive factors
4 affiliations
- 1Urology Department Hamad Medical Corporation Doha Qatar
- 2College of Medicine, QU Health Qatar University Doha Qatar
- 3Department on Internal Medicine Hamad Medical Corporation Doha Qatar
- 4Pharmacy Department, Hamad bin Khalifa Medical City Hamad Medical Corporation Doha Qatar
Abstract
Introduction: Ceftriaxone is a widely used third‐generation cephalosporin in hospitalized patients. Although generally considered safe, it has been associated with hepatobiliary complications and emerging reports of drug‐induced liver injury (DILI). However, data on its true incidence, phenotypic patterns, and predictors remain limited. This study aimed to evaluate the incidence, characterize clinical phenotypes, and identify risk factors for ceftriaxone‐induced liver injury.
Methods: A retrospective cohort study was conducted among adult hospitalized patients who received intravenous ceftriaxone between February 2023 and February 2024. DILI was defined according to predefined biochemical criteria, with additional low‐threshold criteria for early detection. Liver injury phenotypes were classified using the R ratio, and severity was graded according to Drug‐Induced Liver Injury Network (DILIN) criteria. Multivariable logistic regression was performed to identify independent predictors.
Results: Among 739 patients, 244 (33.0%) developed low‐threshold liver test abnormalities, and 143 (19.4%) met biochemical criteria for DILI. Cholestatic injury was the predominant phenotype (46.2%), followed by hepatocellular (29.4%) and mixed patterns (24.5%). Mild and moderate abnormalities occurred in 24.1% and 14.9% of patients, respectively, whereas severe and life‐threatening abnormalities were observed in 7.2% and 7.0%. Longer treatment duration (≥6 days), proton pump inhibitor use, and higher baseline alkaline phosphatase were independently associated with increased odds of DILI.
Conclusion: Ceftriaxone use was associated with a substantial burden of liver test abnormalities, including clinically meaningful elevations. Careful patient selection, limiting treatment duration, and routine liver monitoring may help mitigate DILI risk.
Related
- Extension of penA diversity within the genus Neisseria: characterization of a penA/ftsI homolog in Neisseria bacilliformis associated with elevated ceftriaxone MICs
- Phenotypic Characterization of Multidrug-Resistant Pseudomonas aeruginosa Isolated From Patients With Ventilator-Associated Pneumonia: Insights Into Resistance Mechanisms and Biofilm Formation
- Artificial Intelligence-Enhanced Cardiac Magnetic Resonance in Hypertrophic Cardiomyopathy: Diagnosis, Phenotypic Characterization, and Risk Prediction
- Integrated phenotypic, biochemical and SSR-based characterization of nutraceutical diversity in guava germplasm
- Exercise training inhibits inflammation in adipose tissue via both suppression of macrophage infiltration and acceleration of phenotypic switching from M1 to M2 macrophages in high-fat-diet-induced obese mice
BibTeX
@article{hatem2026ceftriaxoneinduced,
title = {{Ceftriaxone‐induced liver injury: Incidence, phenotypic characterization and predictive factors}},
author = {Mohamed Hatem and Mohannad N. AbuHaweeleh and Humam Emad Rajha and Mhd Osama Rahhal and Ahmad Hamdan and Lina Naseralallah},
journal = {British Journal of Clinical Pharmacology},
year = {2026},
month = jul,
doi = {10.1002/bcp.70657},
url = {https://doi.org/10.1002/bcp.70657},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Ceftriaxone‐induced liver injury: Incidence, phenotypic characterization and predictive factors
AU - Mohamed Hatem
AU - Mohannad N. AbuHaweeleh
AU - Humam Emad Rajha
AU - Mhd Osama Rahhal
AU - Ahmad Hamdan
AU - Lina Naseralallah
PY - 2026
DA - 2026/07/10
JO - British Journal of Clinical Pharmacology
DO - 10.1002/bcp.70657
UR - https://doi.org/10.1002/bcp.70657
AB - Introduction: Ceftriaxone is a widely used third‐generation cephalosporin in hospitalized patients. Although generally considered safe, it has been associated with hepatobiliary complications and emerging reports of drug‐induced liver injury (DILI). However, data on its true incidence, phenotypic patterns, and predictors remain limited. This study aimed to evaluate the incidence, characterize clinical phenotypes, and identify risk factors for ceftriaxone‐induced liver injury. Methods: A retrospective cohort study was conducted among adult hospitalized patients who received intravenous ceftriaxone between February 2023 and February 2024. DILI was defined according to predefined biochemical criteria, with additional low‐threshold criteria for early detection. Liver injury phenotypes were classified using the R ratio, and severity was graded according to Drug‐Induced Liver Injury Network (DILIN) criteria. Multivariable logistic regression was performed to identify independent predictors. Results: Among 739 patients, 244 (33.0%) developed low‐threshold liver test abnormalities, and 143 (19.4%) met biochemical criteria for DILI. Cholestatic injury was the predominant phenotype (46.2%), followed by hepatocellular (29.4%) and mixed patterns (24.5%). Mild and moderate abnormalities occurred in 24.1% and 14.9% of patients, respectively, whereas severe and life‐threatening abnormalities were observed in 7.2% and 7.0%. Longer treatment duration (≥6 days), proton pump inhibitor use, and higher baseline alkaline phosphatase were independently associated with increased odds of DILI. Conclusion: Ceftriaxone use was associated with a substantial burden of liver test abnormalities, including clinically meaningful elevations. Careful patient selection, limiting treatment duration, and routine liver monitoring may help mitigate DILI risk.
SN - 0306-5251
SN - 1365-2125
ER -